Payment overview · 2025
General Payments
$556.58
67 reported records · 9 companies
Healthcare provider profile · identity verified
Dawn M Murray, MD
Allopathic & Osteopathic Physicians|Family Medicine · KEARNEY, NE · NPI 1316021108
Verified facts
What the public records show
CMS Open Payments records show Dawn M Murray, MD received $556.58 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 56.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $314.93 | 56.6% | 52 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $73.64 | 13.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.29 | 10.3% | 3 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $25.84 | 4.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.66 | 4.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.50 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.12 | 2.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.81 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.79 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $556.58 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $218.15 | 48 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $96.78 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.78 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $73.64 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.29 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.29 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.29 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.79 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 83 |
| Lisinopril | Lisinopril | 267 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 61 |
| Omeprazole | Omeprazole | 248 | 51 |
| Potassium Chloride | Potassium Chloride | 230 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 44 |
| Losartan Potassium | Losartan Potassium | 192 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 42 |
| Gabapentin | Gabapentin | 164 | 38 |
| Furosemide | Furosemide | 156 | 26 |
| Sertraline Hcl | Sertraline Hcl | 156 | 32 |
| Metformin Hcl Er | Metformin Hcl | 140 | 34 |
| Simvastatin | Simvastatin | 139 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 25 |
| Glimepiride | Glimepiride | 116 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 26 |
| Meloxicam | Meloxicam | 115 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 21 |
| Tramadol Hcl | Tramadol Hcl | 111 | 25 |
| Montelukast Sodium | Montelukast Sodium | 109 | 32 |
| Metformin Hcl | Metformin Hcl | 107 | 22 |
| Alendronate Sodium | Alendronate Sodium | 102 | 28 |
| Glipizide Er | Glipizide | 93 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Ozempic | Semaglutide | 82 | 14 |
| Spironolactone | Spironolactone | 82 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 18 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 19 |
| Carvedilol | Carvedilol | 64 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | suppressed |
| Eliquis | Apixaban | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Jardiance | Empagliflozin | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 15 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Prednisone | Prednisone | 24 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Xiidra | Lifitegrast | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $556.58 · 67 records | ABBVIE INC. | ABRYSVO, CAMZYOS, COMIRNATY, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, Ozempic, PREVNAR 20, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Xeomin | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error